Incyte

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 2,600 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.

Shilpa Pharma, Inc.

Shilpa Pharma, Inc. is the US operating company of Shilpa Medicare Limited, one of the largest specialty generic pharmaceutical companies in the world. Based in India, they have API and finished formulation production facilities while providing high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries globally. Shilpa Medicare Limited is establishing collaborations including in/out-licensing of products and technologies, strategic alliances, joint ventures, and mergers and acquisitions as they strengthen their presence in other markets across the world. Shilpa Pharma, Inc. will develop and support these collaborations here in the US. To learn more, please visit vbshilpa.com.

LENZ Therapeutics

LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.

Plexus Ventures LLC

Plexus Ventures is a prominent healthcare advisory boutique. Our team of professionals are located in markets all over the world – the United States, Europe, and the Asia-Pacific market, including China and Japan – enabling us to combine local knowledge with global reach.

ELRIG UK

The European Laboratory Research and Innovation Group UK (ELRIG) is a not for profit company whose purpose is to bring the life science and drug discovery communities together to learn, share, connect, innovate and collaborate. We achieve this through the provision of world class conferences, networking events, webinars and digital content. Our values are to always ensure the highest quality of content and that content will be made readily accessible to all, and that we will always be an inclusive organisation, serving a diverse scientific community. In addition, ELRIG will always be a volunteer led organisation, run by the life sciences community, for the life sciences community, on a not for profit basis. ELRIG has evolved from the Laboratory Robotics Interest Groups set up in North America in the early 2000’s, and has become an independent commercial enterprise, with no major benefactors nor significant funding from a single source. Instead ELRIG depends on key partners to provide rent-free venues and the vendor community to purchase sponsorship opportunities at its events. ELRIG is unique in that it considers vendors to be very much part of the life science community and incorporates presentations on their innovations into its podium programming. Led by a board of volunteers, and run by a small team of employees, ELRIG successfully hosts at least 5 conferences and 5 networking events per year, which bring together world class speakers, that present the latest research and innovation from their laboratories. Events vary in size from 40 attendees at our tier 2 events (primarily networking or webinars), to 300 plus attendees at our tier 1 events (primarily 1 to 2 day conferences), to greater than 1500 attendees at our flag ship Drug Discovery meeting. All these events are run as free-to-attend, with speaker expenses and delegate subsistence paid for by ELRIG, which is only possible due to the support of its sponsors.